Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

211 Press Releases
DateTitleCompany
20 Oct 17 Astellas and Universal Cells, Inc. Announce a Collaboration Utilizing Universal Donor Cell Technology Astellas Pharma Inc.,
Published by
PR Newswire
11 Oct 17 U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia Astellas Pharma Inc.,
Published by
PR Newswire
24 Aug 17 First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteritinib as Maintenance Therapy Following Hematopoietic Stem Cell Transplant in Patients with FLT3 Mutation-positive Acute Myeloid Leukemia Astellas Pharma ,
Published by
PharmiWeb.com
28 Jul 17 Astellas Reports First Quarter FY2017 Financial Results Astellas Pharma Inc.,
Published by
Business Wire
20 Jul 17 U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia Astellas,
Published by
PharmiWeb.com
19 Jul 17 Astellas Farma Brasil named a top-ten pharmaceutical company to work for in Brazil Astellas Farma Brasil,
Published by
PR Newswire
13 Jul 17 Astellas Head of Medical Affairs Americas Shontelle Dodson Joins National Pharmaceutical Council Board of Directors Astellas,
Published by
PR Newswire
30 Jun 17 Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder Astellas ,
Published by
PharmiWeb.com
30 Jun 17 Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder Astellas Pharma Inc.,
Published by
PR Newswire
26 Jun 17 The Lancet Oncology Publishes Anti-Leukemic Activity and Safety Data for gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia Astellas,
Published by
PharmiWeb.com
20 Jun 17 The Astellas Oncology C3 Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants Astellas Pharma Inc.,
Published by
PR Newswire
20 Jun 17 The Astellas Oncology C(3) Prize Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants Astellas Pharma Canada, Inc.,
Published by
PR Newswire
27 May 17 Great Place to Work® and Fortune Name Astellas to Inaugural Best Workplaces in Chicago List Astellas Pharma ,
Published by
PharmiWeb.com
23 May 17 Action on Fistula to transform 4,500 lives by 2020 Astellas Pharma Europe
22 May 17 Astellas Named 2017 When Work Works Honoree by the Society for Human Resource Management Astellas ,
Published by
PharmiWeb.com
22 May 17 Astellas Announces Oncology Portfolio Updates Astellas ,
Published by
PharmiWeb.com
22 May 17 Astellas Announces Record Number of Abstracts Highlighting Breadth and Depth of Oncology Portfolio Data to be Presented at 2017 ASCO Annual Meeting Astellas ,
Published by
PharmiWeb.com
27 Apr 17 Astellas To Present on Challenges to Health Innovation at Milken Institute Global Conference Astellas,
Published by
PR Newswire
24 Apr 17 Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence[1] Astellas Pharma EMEA,
Published by
PR Newswire
24 Apr 17 Use of Extended-Pulsed Regimen with DIFICLIR[TM] (fidaxomicin) is More Effective Than Standard vancomycin in Achieving Sustained Cure of Clostridium difficile Infection (CDI) and Preventing Recurrence[1] Astellas Pharma EMEA,
Published by
PR Newswire
30 Jan 17 Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan Ironwood Pharmaceuticals, Inc. & Astellas Pharma Inc.,
Published by
Business Wire
08 Dec 16 Astellas Research & Development Meeting Highlights Astellas Pharma Inc.,
Published by
Business Wire
21 Apr 17 New Study Reveals the Impact of Clostridium difficile Infection (CDI) on the Health Service is Equivalent to an Additional 10,670 Bed Days a Year Astellas Pharma EMEA,
Published by
PR Newswire
18 Jan 17 Astellas Announces Participation in Access Accelerated Astellas Pharma Inc.,
Published by
PR Newswire
27 Jan 17 Over 2,000 women's lives transformed by Action on Fistula Astellas Pharma EMEA
26 Jan 17 OVER 2,000 WOMENS LIVES TRANSFORMED BY ACTION ON FISTULA Astellas Pharma EMEA
08 Feb 17 Astellas Names Linda Friedman General Counsel for Worldwide Legal Organization and Executive Committee Member Astellas,
Published by
PR Newswire
31 Mar 17 Astellas Announces New President of Astellas US Technologies, Inc. Astellas,
Published by
PR Newswire
21 Dec 16 Astellas Completes Acquisition of Ganymed Pharmaceuticals Astellas Pharma Inc.,
Published by
PR Newswire
31 Jan 17 Astellas Reports the First Nine Months Financial Results of FY2016 Astellas Pharma Inc.,
Published by
Business Wire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.